Recently, L’Oréal, the world’s largest beauty company, is reportedly the leading contender to acquire Medik8, the fast-growing U.K.-based skincare brand, according to WWD. It is reported that while both companies have declined to comment on the potential deal, insiders suggest that L’Oréal has pulled ahead of other interested parties, positioning itself as the likely buyer.
Founded in 2009 by Elliot Isaacs, Medik8 has built a strong reputation in the dermocosmetics space—a sector increasingly favored by investors for its positioning at the intersection of topicals, aesthetics, and professional skincare services.
The brand has seen significant growth, with 2024 sales rising 50 percent and global revenues projected to reach $115 million in 2025. Medik8’s clinical-grade products, such as its Crystal Retinal Serum (named one of WWD Beauty Inc’s 100 Greatest Skincare Products of All Time), and its newly launched Liquid Peptides Advanced MP serum, have helped drive expansion, particularly in the U.S. market.
If completed, the acquisition would further bolster L’Oréal’s Dermatological Beauty Division, already home to category leaders like La Roche-Posay, SkinCeuticals, and CeraVe. With more than 300 employees and a presence in over 7,000 clinics worldwide, Medik8 would be a strategic fit, aligning with L’Oréal’s ongoing investment in science-driven, high-performance skincare.
